FDA Brief

Warning letters Drugs

FDA warning letter to

Rite-Kem Incorporated

High riskIssued Jan 28, 2025Posted Mar 18, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.

What happened

FDA inspected Rite-Kem's drug manufacturing facility in Tupelo, Mississippi, from September 9 to 12, 2024. The agency found that Rite-Kem released over-the-counter drug batches without adequate finished-product identity, strength, or microbial testing; did not adequately test components such as glycerin for diethylene glycol or ethylene glycol, or an incoming active ingredient for methanol; and lacked adequate quality-unit oversight.

What FDA found

  1. Rite-Kem did not test each finished drug batch for the identity and strength of active ingredients or for microorganisms before release.

    21 CFR 211.165(a)
  2. Rite-Kem did not perform identity testing on each component lot and relied on supplier certificates of analysis without establishing their reliability.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. Rite-Kem did not test each glycerin lot for diethylene glycol or ethylene glycol using the United States Pharmacopeia identity test.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  4. Rite-Kem did not test an incoming active ingredient for methanol, a toxic impurity.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  5. Rite-Kem's quality unit did not ensure adequate process and equipment validation, written procedures, employee training, batch records, stability testing, or cleaning and cleaning validation.

    21 CFR 211.22; 211.100(a); 211.22(d); 211.25(a); 211.188(b); 211.166(a); 211.67(a)-(b)
  6. Rite-Kem's drug products are adulterated because its manufacturing methods, facilities, or controls do not conform to CGMP.

    section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA tells Rite-Kem to respond in writing within 15 working days with corrective action plans, testing and supplier-qualification information, and risk assessments, including diethylene glycol and ethylene glycol test results within 30 calendar days. Rite-Kem must also notify FDA before resuming drug manufacturing.

Who should pay attention

  • brands or retailers that buy Rite-Kem over-the-counter drugs
  • contract manufacturers of hand sanitizers or antimicrobial products
  • buyers and suppliers of glycerin or other high-risk drug components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk